PATENT CLAIM ANALYSIS

Application Number: 16028140
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-06
Patent Classification: ["424", "133100"]

Abstract:
The present inventors newly discovered that even if an antigen-binding molecule inhibits in vitro some of the physiological activities of an antigen having two or more physiological activities without inhibiting the remaining physiological activities, the molecule can promote elimination of the antigen from blood (from serum or plasma) and as a result reduce the physiological activities in vivo, when the antigen-binding molecule is conferred with the properties: (i) of binding to human FcRn wider an acidic pH range condition; (ii) of binding under a neutral pH range condition to human Fc receptor stronger than native human IgG, and (iii) that its antigen-binding activity alters according to the ion concentration.

Claim (Index 62):
The method of  claim 61 , wherein the one or more positions include at least one from the following positions (all by EU numbering), substituted with the indicated amino acid:\n position 234: Arg; position 235: Gly, Lys, or Arg; position 236: Ala, Asp, Lys, or Arg; position 237: Lys, Met, or Arg; position 238: Ala, Asp, Lys, Leu, or Arg; position 239: Asp or Lys; position 244: Leu; position 245: Arg; position 248: Ile or Tyr; position 249: Pro; position 250: Ala, Glu, Phe, Ile, Met, Gln, Ser, Val, Trp, Gly, His, Leu, Asn, or Tyr; position 251: Arg, Asp, Glu, or Leu; position 252: Phe, Ser, Thr, Trp, or Tyr; position 253: Val; position 254: Ala, Gly, His, Ile, Gln, Ser, Val, or Thr; position 255: Ala, Asp, Phe, His, Ile, Lys, Leu, Met, Asn, Gln, Arg, Gly, Ser, Trp, Tyr, or Glu; position 256: Ala, Asp, Glu, Arg, Asn, Pro, Thr, Ser, or Gln; position 257: Ala, Gly, Ile, Leu, Met, Asn, Ser, Thr, or Val; position 258: Asp or His; position 260: Ser; position 262: Leu; position 265: Ala; position 267: Met or Leu; position 270: Lys or Phe; position 272: Ala, Leu, or Arg; position 274: Ala; position 279: Leu, Ala, Asp, Gly, His, Met, Asn, Gln, Arg, Ser, Thr, Trp, or Tyr; position 280: Ala, Gly, His, Lys, Asn, Gln, Arg, Ser, Thr, or Glu; position 282: Ala or Asp; position 283: Ala, Asp, Phe, Gly, His, Ile, Lys, Leu, Asn, Pro, Gln, Arg, Ser, Thr, Trp, or Tyr; position 284: Lys; position 285: Asn; position 286: Ala, Asp, Phe, Gly, His, Ile, Lys, Leu, Met, Pro, Gln, Arg, Ser, Thr, Val, Trp, Tyr, or Glu; position 288: Ala, Asp, Glu, Phe, Gly, His, Ile, Leu, Met, Asn, Pro, Gln, Arg, Val, Trp, Tyr, or Ser; position 289: His; position 293: Val; position 295: Met; position 297: Ala; position 298: Gly; position 303: Ala; position 305: Ala or Thr; position 307: Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Val, Trp, or Tyr; position 308: Ala, Phe, Ile, Leu, Met, Pro, Gln, or Thr; position 309: Ala, Asp, Glu, Pro, His, or Arg; position 311: Ala, His, Glu, Lys, Leu, Met, Ser, Val, Trp, or Ile; position 312: Ala, Asp, Pro, or His; position 313: Tyr or Phe; position 314: Ala, Leu, Lys, or Arg; position 315: Ala, Asp, Glu, Phe, Gly, Ile, Lys, Leu, Met, Gln, Arg, Ser, Thr, Val, Trp, Tyr, or His; position 316: Ala, Glu, Phe, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, or Asp; position 317: Ala or Pro; position 318: Asn or Thr; position 325: Ala, Gly, Met, Leu, Ile, or Ser; position 326: Asp; position 327: Gly; position 328: Arg, Asp, Glu, or Tyr; position 329: Lys or Arg; position 330: Leu; position 332: Glu, Phe, His, Lys, Leu, Met, Arg, Ser, Trp, or Val; position 334: Leu; position 338: Ala; position 339: Asn, Thr, or Trp; position 340: Ala; position 341: Pro; position 343: Glu, His, Lys, Gln, Arg, Thr, or Tyr; position 345: Ala; position 360: His; position 361: Ala; position 362: Ala; position 375: Ala or Arg; position 376: Ala, Gly, Ile, Met, Pro, Thr, or Val; position 377: Lys; position 378: Asp, Asn, or Val; position 380: Ala, Asn, Thr, or Ser; position 382: Ala, Phe, His, Ile, Lys, Leu, Met, Asn, Gln, Arg, Ser, Thr, Trp, Tyr, or Val; position 384: Ala; position 385: Ala, Gly, Lys, Ser, Thr, Asp, His, or Arg; position 386: Arg, Asp, Ile, Met, Ser, Thr, Lys, or Pro; position 387: Ala, Arg, His, Pro, Ser, Thr, or Glu; position 389: Ala, Asn, Pro, or Ser; position 390: Ala; position 391: Ala; position 413: Ala; position 423: Asn; position 424: Ala or Glu; position 427: Asn; position 428: Ala, Asp, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Ser, Thr, Val, Trp, or Tyr; position 430: Ala, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Gln, Arg, Ser, Thr, Val, or Tyr; position 431: His or Asn; position 433: Arg, Gln, His, Ile, Pro, Ser, or Lys; position 434: Ala, Phe, Gly, Met, His, Ser, Trp, or Tyr; position 435: Lys, Arg, or Asn; position 436: Ala, His, Ile, Leu, Glu, Phe, Gly, Lys, Met, Asn, Arg, Ser, Thr, Trp, or Val; position 437: Arg; position 438: Lys, Leu, Thr, or Trp; position 440: Lys; and position 442: Lys.

Metadata:
- Claim Count in Document: 56.0
- Percentile: 95.0
- Lexical Diversity: 1.5974
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14007947', '14347448', '14101441', '13650493', '09825517']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7745399711331559
- 35 USC 102 Novelty (BERT): 0.7482263337622165
- Combined Prediction Score: 0.7719086073960619
- Mean Citation Score: 761.1392320000001
- Max Citation Score: 1081.3811
- Similarity Product: 838.7694737510623

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test